Precision. Quality. Integrity.

About Us

Established in 2019, Cephas Life Sciences (CLS) Private Limited provides specialized analytical and research services for the global pharmaceutical and medical device industries.

CLS Laboratory at TICEL Bio Park

Who We Are

Cephas Life Sciences (CLS) Private Limited was established in July 2019 with a singular vision: to provide specialized analytical and research services for pharmaceuticals and medical device products.

Our mission is to meet — and exceed — customer expectations in terms of quality, delivery, and cost. At CLS, we are committed to adding value by offering need-based pre and post-support services to help our customers meet their regulatory and research requirements.

Our expertise lies in conducting both qualitative and quantitative studies, with deep specialization in the testing of extractables and leachables — one of the most critical areas of pharmaceutical safety.

Industries We Serve

Pharmaceutical
Pharmaceutical Packaging
Medical Devices

Our Vision

To be the preferred partner for specialized analytical and research services, enabling pharmaceutical and medical device companies to bring safe, effective products to market.

Our Mission

To meet and exceed customer expectations in terms of quality, agility, and economy — delivering results that regulatory bodies worldwide trust.

Our Commitment

Adding value through need-based pre and post-support services, ensuring our customers meet their regulatory and research requirements with absolute confidence.

Our Impact

0+

Years Combined Experience

0+

Projects Supported

0

Industry Sectors

0+

Customers Across India

0+

Customers from TN

0+

Global Customers

Our Journey

Milestones & Achievements

A proven track record of rapid regulatory compliance and global accreditations.

Drugs Control & Licensing
NABL / ISO:17025
USFDA
2020
Oct

Drugs Control Licensing Authority - Inspection

2021
JAN

Drug License in Form 37

Feb

ISO/IEC 17025:2017 NABL Accreditation

Dec

USFDA Registration (DUNS)

2022
Mar

NABL Surveillance Completed

2023
May

USFDA Inspection & EIR Received

EIR received in July.

Feb

NABL 1st Renewal Accreditation

2024
Dec

NABL 2nd Renewal Accreditation

May

Medical Device Form MD 40

2025
Feb

USFDA Inspection & EIR Received

EIR received in May.

2026
Jan

NABL Onsite Surveillance

Our People

Meet Our Leadership

Dr. B Philip Ashok Karunakaran

Dr. B Philip Ashok Karunakaran

Co-Founder & Director

With over three decades of distinguished experience in pharmaceutical sciences, our leadership is committed to delivering uncompromised analytical excellence, fostering global regulatory compliance, and building a foundation of absolute trust.

PhD in Pharmaceutical Quality Management

Extensive expertise in pharmaceutical science and quality systems.

30+ Years Industry Experience

Proven track record of building successful teams and achieving corporate goals.

Senior Management Leader

Held key strategic positions across highly reputed global organizations.

Our Scientific Team

Our technical and quality assurance teams are led by experienced managers with over a decade of specialization in trace analysis and mass spectrometric techniques.

Mass Spectrometry

Advanced LC-MS/MS, GC-MS/MS, and ICP-MS techniques for trace-level detection.

Trace Analysis

Detecting and quantifying compounds at parts-per-billion levels with unparalleled precision.

Method Development

Creating robust, sensitive, and specific analytical methods for complex pharmaceutical matrices.

Method Validation

ICH-compliant validation ensuring reproducibility, accuracy, and regulatory acceptance.

Qualitative & Quantitative Studies

Precise quantification of unknown compounds and impurities.

Research & Development

Supporting novel research initiatives with cutting-edge analytical capabilities.

Need Analytical Testing?

Talk to our experts today to discuss your project requirements and timelines.